Crispr Therapeutics AG (CRSP) is near the top in its industry group according to InvestorsObserver. CRSP gets an overall rating of 46. That means it scores higher than 46 percent of stocks. Crispr Therapeutics AG gets a 74 rank in the Biotechnology industry. Biotechnology is number 103 out of 148 industries.
What do These Ratings Mean?
Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. InvestorsObserver allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 46 would rank higher than 46 percent of all stocks.
Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes
’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.
What's Happening With Crispr Therapeutics AG Stock Today?
Crispr Therapeutics AG (CRSP) stock is down -1.53% while the S&P 500 has gained 0.09% as of 11:39 AM on Tuesday, Aug 10. CRSP is down -$2.12 from the previous closing price of $137.82 on volume of 507,814 shares. Over the past year the S&P 500 has risen 32.02% while CRSP has gained 49.51%. CRSP earned $5.11 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 26.48.